Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$897.00K$897.00Kderivedno prior Q4 2018 on file Net Income$6.67M$6.67MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$6,604,000N/M Operating Cash Flowderived-$5,978,000N/M Margins · derivedOperating margin-736.2%
Net margin743.9%
ended Dec 31, 2019 · filed Mar 16, 2020 · 76 d after period end